155 related articles for article (PubMed ID: 10999464)
1. Soluble Fas/Apo-1 (CD95) levels during T cell activation in the presence of acute myelogenous leukemia accessory cells; contributions from local release and variations in systemic levels.
Bruserud O; Ulvestad E
Cancer Immunol Immunother; 2000 Sep; 49(7):377-87. PubMed ID: 10999464
[TBL] [Abstract][Full Text] [Related]
2. [Expression of Fas receptor and soluble Fas ligand (sFasL) concentration in acute leukemia].
Urbaniak-Kujda D; Jaźwiec B; Tomaszewska-Toporska B; Wołowiec D; Kapelko-Słowik K; Kuliczkowski K
Pol Arch Med Wewn; 2002 Sep; 108(3):873-8. PubMed ID: 12600184
[TBL] [Abstract][Full Text] [Related]
3. T-lymphocyte functions in acute leukaemia patients with severe chemotherapy-induced cytopenia: characterization of clonogenic T-cell proliferation.
Bruserud O; Ulvestad E; Berentsen S; Bergheim J; Nesthus I
Scand J Immunol; 1998 Jan; 47(1):54-62. PubMed ID: 9467659
[TBL] [Abstract][Full Text] [Related]
4. Elevation of soluble Fas and soluble Fas ligand in reactive macrophage activation syndromes.
Emmenegger U; Zehnder R; Frey U; Reimers A; Spaeth PJ; Neftel KA
Am J Hematol; 2000 Jun; 64(2):116-9. PubMed ID: 10814991
[TBL] [Abstract][Full Text] [Related]
5. Correlation of loss of CD4 T cells with plasma levels of both soluble form Fas (CD95) Fas ligand (FasL) in HIV-infected infants.
Hosaka N; Oyaizu N; Than S; Pahwa S
Clin Immunol; 2000 Apr; 95(1 Pt 1):20-5. PubMed ID: 10794428
[TBL] [Abstract][Full Text] [Related]
6. VEINCTR-N, an immunogenic epitope of Fas (CD95/Apo-I), and soluble Fas enhance T-cell apoptosis in vitro. II. Functional analysis and possible implications in HIV-1 disease.
Silvestris F; Cafforio P; Tucci M; Del Prete A; Dammacco F
Mol Med; 2000 Jun; 6(6):509-26. PubMed ID: 10972087
[TBL] [Abstract][Full Text] [Related]
7. Plasma-soluble Fas (APO-1, CD95) and soluble Fas ligand in immune thrombocytopenic purpura.
Yoshimura C; Nomura S; Nagahama M; Ozaki Y; Kagawa H; Fukuhara S
Eur J Haematol; 2000 Apr; 64(4):219-24. PubMed ID: 10776692
[TBL] [Abstract][Full Text] [Related]
8. Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in advanced melanoma.
Mouawad R; Khayat D; Soubrane C
Melanoma Res; 2000 Oct; 10(5):461-7. PubMed ID: 11095407
[TBL] [Abstract][Full Text] [Related]
9. Effects of imipenem and cilastatin on human T-lymphocytes derived from acute leukemia patients with chemotherapy-induced leucopenia: studies of T-lymphocyte responses in the presence of acute myelogenous leukemia (AML) blast accessory cells.
Bruserud O
Int J Immunopharmacol; 2000 Jan; 22(1):69-81. PubMed ID: 10684990
[TBL] [Abstract][Full Text] [Related]
10. Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases.
Nozawa K; Kayagaki N; Tokano Y; Yagita H; Okumura K; Hasimoto H
Arthritis Rheum; 1997 Jun; 40(6):1126-9. PubMed ID: 9182923
[TBL] [Abstract][Full Text] [Related]
11. mRNA expression of variant Fas molecules in acute leukemia cells.
Inaba H; Komada Y; Li QS; Zhang XL; Tanaka S; Azuma E; Yamamoto H; Sakurai M
Am J Hematol; 1999 Nov; 62(3):150-8. PubMed ID: 10539881
[TBL] [Abstract][Full Text] [Related]
12. Increased serum levels of soluble Fas in progressive B-CLL.
Osorio LM; Aguilar-Santelises M; De Santiago A; Hachiya T; Mellstedt H; Jondal M
Eur J Haematol; 2001 May; 66(5):342-6. PubMed ID: 11422415
[TBL] [Abstract][Full Text] [Related]
13. Serum soluble Fas (CD95) and Fas ligand profiles in chronic kidney failure.
Perianayagam MC; Murray SL; Balakrishnan VS; Guo D; King AJ; Pereira BJ; Jaber BL
J Lab Clin Med; 2000 Oct; 136(4):320-7. PubMed ID: 11039853
[TBL] [Abstract][Full Text] [Related]
14. Serum levels of soluble Fas/APO-1 receptor in human retroviral infection and associated diseases.
Kamihira S; Yamada Y; Hiragata Y; Yamaguchi T; Izumikawa K; Matsuo Y; Sugahara K; Tsuruta K; Atogami S; Tsukasaki K; Maeda T; Tomonaga M
Intern Med; 1997 Mar; 36(3):166-70. PubMed ID: 9144006
[TBL] [Abstract][Full Text] [Related]
15. Associations of serum soluble Fas and Fas ligand (FasL) with outcomes in systemic lupus erythematosus.
Vincent FB; Kandane-Rathnayake R; Koelmeyer R; Harris J; Hoi AY; Mackay F; Morand EF
Lupus Sci Med; 2020 Jun; 7(1):. PubMed ID: 32546562
[TBL] [Abstract][Full Text] [Related]
16. Prolonged intrathecal release of soluble Fas following severe traumatic brain injury in humans.
Lenzlinger PM; Marx A; Trentz O; Kossmann T; Morganti-Kossmann MC
J Neuroimmunol; 2002 Jan; 122(1-2):167-74. PubMed ID: 11777556
[TBL] [Abstract][Full Text] [Related]
17. Effects of gamma-irradiation on acute myelogenous leukemia blasts: in vitro studies of proliferation, constitutive cytokine secretion, and accessory cell function during T cell activation.
Bruserud O; Ulvestad E
J Hematother Stem Cell Res; 1999 Aug; 8(4):431-41. PubMed ID: 10634181
[TBL] [Abstract][Full Text] [Related]
18. Soluble Fas and Fas ligand and prognosis in children with acute lymphoblastic leukemia.
Fathi M; Amirghofran Z; Shahriari M
Med Oncol; 2012 Sep; 29(3):2046-52. PubMed ID: 21528407
[TBL] [Abstract][Full Text] [Related]
19. Membrane and soluble forms of Fas (CD95) and Fas ligand in peripheral blood mononuclear cells and in plasma from human immunodeficiency virus-infected persons.
Hosaka N; Oyaizu N; Kaplan MH; Yagita H; Pahwa S
J Infect Dis; 1998 Oct; 178(4):1030-9. PubMed ID: 9806031
[TBL] [Abstract][Full Text] [Related]
20. Fas receptor-Fas ligand system is independent of both CD34 status and chemosensitivity in acute myeloid leukemia.
Lewis NR; Pallis M; Russell NH
Exp Hematol; 2000 May; 28(5):535-42. PubMed ID: 10812243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
